Clinical trial

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

NCT03084471

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention MEDI4736 (Durvalumab) Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention MEDI4736 (Durvalumab) + Tremelimumab Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-05

PhasePHASE3

Conditions

Advanced Solid Malignanciesunresolved

Interventions

MEDI4736 (Durvalumab)BIOLOGICAL

MEDI4736 (Durvalumab) + TremelimumabBIOLOGICAL

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

LondonUnited Kingdom3 TorontoOntario, Canada2 SeoulSouth Korea2 RomaItaly2 BordeauxFrance2 ParisFrance1 BerlinGermany1 Washington D.C.District of Columbia, United States1 MilanItaly1 OmahaNebraska, United States1 HamburgGermany1 ToulouseFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03084471 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.